Search

Your search keyword '"Machado-Duque, Manuel Enrique"' showing total 182 results
Start Over Author "Machado-Duque, Manuel Enrique"
182 results on '"Machado-Duque, Manuel Enrique"'

6. Use of sacubitril/valsartan in patients with heart failure: evidence from the real world

Author

Valladales-Restrepo, Luis Fernando, primary, Sánchez-Ramírez, Nicolás, additional, Usma-Valencia, Andrés Felipe, additional, Velásquez-Quirama, Santiago, additional, Henao-Martínez, Manuela, additional, Castro-Rodriguez, Jorge Alejandro, additional, Gaviria-Mendoza, Andrés, additional, Machado-Duque, Manuel Enrique, additional, and Machado-Alba, Jorge Enrique, additional

Published
2023
Full Text
View/download PDF

9. Antibiotic Management of Uncomplicated Skin and Soft Tissue Infections in the Real World

Author

Valladales-Restrepo, Luis Fernando, primary, Aristizábal-Carmona, Brayan Stiven, additional, Giraldo-Correa, Jaime Andrés, additional, Acevedo-Medina, Luis Felipe, additional, Valencia-Sánchez, Laura, additional, Acevedo-López, Doménica Tatiana, additional, Gaviria-Mendoza, Andrés, additional, Machado-Duque, Manuel Enrique, additional, and Machado-Alba, Jorge Enrique, additional

Published
2023
Full Text
View/download PDF

15. Study of Prescription-Indication of Outpatient Systemic Anti-Fungals in a Colombian Population. A Cross-Sectional Study

Author

Valladales-Restrepo, Luis Fernando, primary, Ospina-Cano, Juan Alberto, additional, Aristizábal-Carmona, Brayan Stiven, additional, López-Caicedo, Diana Fiorella, additional, Toro-Londoño, Melissa, additional, Gaviria-Mendoza, Andrés, additional, Machado-Duque, Manuel Enrique, additional, and Machado-Alba, Jorge Enrique, additional

Published
2022
Full Text
View/download PDF

16. Satisfaction with and Use of Inhalation Devices in Patients with Bronchial Asthma

Author

Valladales-Restrepo, Luis Fernando, primary, Saavedra-Navia, Juan Camilo, additional, Montezuma-Casanova, Carlos Andrés, additional, Montañez-Díaz, Valentina, additional, González-Ospina, Jairo Andrés, additional, Caballero-Martínez, Laura Manuela, additional, Gaviria-Mendoza, Andrés, additional, Machado-Duque, Manuel Enrique, additional, and Machado-Alba, Jorge Enrique, additional

Published
2022
Full Text
View/download PDF

22. Chronic pain and continuity of analgesic treatment during the COVID‐19 pandemic.

Author

Valladales‐Restrepo, Luis Fernando, Gaviria‐Mendoza, Andrés, Machado‐Duque, Manuel Enrique, Prado‐Echeverry, Julio Andrés, Cortés‐Navarro, Jorge Luis, and Machado‐Alba, Jorge Enrique

Subjects
CHRONIC pain & psychology, CHRONIC pain, CANCER pain, HEALTH services accessibility, CONFIDENCE intervals, ANALGESICS, CHRONIC diseases, NONOPIOID analgesics, MENTAL health, RETROSPECTIVE studies, ACQUISITION of data, MEDICAL records, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, OPIOID analgesics, COVID-19 pandemic, PAIN management, LONGITUDINAL method
Abstract

Introduction: Chronic pain can trigger both physical and mental health complications. During the COVID‐19 pandemic, patients with chronic diseases have had reduced access to some medications. Objective: To determine the pharmacological management of patients with chronic pain and its continuity during the COVID‐19 pandemic. Methods: This was a retrospective longitudinal study of the continuity of analgesic use in patients with chronic pain between September 1, 2019 and February 28, 2021 based on a drug dispensing database. Survival analysis was performed until the discontinuation of chronic analgesics. Results: A total of 12,701 patients who were being treated for chronic pain were identified. Their median age was 70.3 years, and 74.4% were women. The pain of rheumatological origin was the most frequent etiology (46.1%); the most used medications were nonopioid analgesics (78.9%), pain modulators (24.8%) and opioid analgesics (23.3%). A total of 76.1% of the patients experienced interruptions in their management during the study period. The median time to the first interruption of treatment was 5.0 months (95% CI: 4.8–5.2). Those who were treated for oncological pain experienced a greater number of interruptions in their management. Conclusions: The pharmacological management of patients with chronic pain is heterogeneous, and this real‐world study showed that a high proportion of patients experienced an interruption of pain management during the 12 months following the onset of the COVID‐19 pandemic. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Indicación y prescripción de macrólidos en una población colombiana

Author

Valladales-Restrepo, Luis Fernando, Constain-Mosquera, Camilo Alexander, Hoyos-Guapacha, María Alejandra, Hoyos-Guapacha, Karol Liceth, Gaviria-Mendoza, Andrés, Machado-Duque, Manuel Enrique, and Machado-Alba, Jorge Enrique

Subjects
azithromycin, macrólidos, coronavirus infections, pharmacoepidemiology, infecciones por coronavirus, pneumonia, neumonía, farmacoepidemiología, inappropriate prescribing, Macrolides, Colombia, azitromicina, prescripción inadecuada
Abstract

Resumen Introducción. El uso inadecuado de antibióticos se asocia con aumento de la resistencia antimicrobiana, mayores costos de atención médica, más efectos adversos y peores resultados clínicos. Objetivo. Determinar los patrones de prescripción y las indicaciones aprobadas y no aprobadas para macrólidos en un grupo de pacientes en Colombia. Materiales y métodos. Se hizo un estudio de corte transversal sobre las indicaciones de uso de macrólidos en pacientes ambulatorios a partir de una base de datos de dispensación de medicamentos de 8,5 millones, aproximadamente, de personas afiliadas al sistema de salud de Colombia. Se consideraron variables sociodemográficas, farmacológicas y clínicas. Resultados. Se encontraron 9.344 pacientes que habían recibido prescripción de macrólidos; su mediana de edad era de 40,1 años (rango intercuartílico: 27,1-53,3 años) y el 58,3 % correspondía a mujeres. El macrólido más prescrito fue la azitromicina (38,8 %) y los usos más frecuentes fueron el tratamiento de la infección por Helicobacter pylori (15,9 %) y la neumonía (15,8 %). El 31,3 % de las prescripciones correspondía a indicaciones no aprobadas, destacándose el resfriado común (7,8 %), la Covid-19 (4,0 %) y la bronquitis aguda (3,5 %). La residencia en la región Caribe (OR=1,17; IC95% 1,05-1,31), las prescripciones odontológicas (OR=2,75; IC95% 1,91-3,96), las comorbilidades respiratorias crónicas (OR=1,30; IC95% 1,08-1,56), y la prescripción de eritromicina (OR=3,66; IC95% 3,24-4,14) o azitromicina (OR=2,15; IC95% 1,92 2,41), se asociaron con una mayor probabilidad de recibir macrólidos para indicaciones no aprobadas, en tanto que tener entre 18 y 64 años (OR=0,81; IC95% 0,71-0,93), 65 o más años (OR=0,77; IC95% 0,63-0,94) y residir en Bogotá-Cundinamarca (OR=0,74; IC95% 0,65 0,85) reducían dicho riesgo. Conclusiones. La mayoría de los pacientes recibieron macrólidos para infecciones del sistema respiratorio; la eritromicina y la azitromicina se prescribieron en indicaciones no aprobadas en menores de 18 años y en quienes presentaban enfermedades respiratorias crónicas. Abstract Introduction: The inappropriate use of antibiotics is associated with a greater risk for antimicrobial resistance, high health care costs, adverse events, and worse clinical outcomes. Objective: To determine the prescription patterns and approved and nonapproved indications for macrolides in a group of patients from Colombia. Materials and methods: This was a cross-sectional study on the indications for the use of macrolides in outpatients registered in a drug-dispensing database of approximately 8.5 million people affiliated with the Colombian health system. Sociodemographic, pharmacological, and clinical variables were considered. Results: A total of 9.344 patients had received a macrolide prescription; their median age was 40.1 years (interquartile range: 27.1-53.3 years) and 58.3% were women. The most commonly prescribed macrolide was azithromycin (38.8%) most frequently for Helicobacter pylori infection (15.9%) and pneumonia treatment (15.8%). A total of 31.3% of the prescriptions were used for unapproved indications: common cold (7.8%), COVID-19 (4.0%), and acute bronchitis (3.5%). Residence in the Caribbean region (OR=1.17; 95%CI 1.05-1.31), dental prescriptions (OR=2.75; 95%CI 1.91-3.96), presence of chronic respiratory comorbidities (OR=1.30; 95%CI 1.08-1.56), and prescription of erythromycin (OR=3.66; 95%CI 3.24-4.14) or azithromycin (OR=2.15; 95%CI 1,92-2.41) were associated with a higher probability of macrolide use for unapproved indications while being 18-64 years old (OR=0.81; 95%CI 0.71-0.93) or 65 years or older (OR=0.77; 95%CI 0.63-0.94) and residing in Bogotá-Cundinamarca (OR=0.74; 95%CI 0.65-0.85) were associated with reduced risk. Conclusions: Most patients received macrolides for respiratory tract infections; erythromycin and azithromycin were used for unapproved indications in people under 18 years of age and those with chronic respiratory diseases.

Published
2022

26. Are we controlling postoperative pain?

Author

Machado-Alba, Jorge Enrique, Machado-Duque, Manuel Enrique, Calderón Flórez, Viviana, Gonzalez Montoya, Alexandra, Cardona Escobar, Felipe, Ruiz García, Richard, and Montoya Cataño, Julian

Published
2013
Full Text
View/download PDF

29. Factors associated with admission to the intensive care unit and mortality in patients with COVID-19, Colombia

Author

Machado-Alba, Jorge Enrique, primary, Valladales-Restrepo, Luis Fernando, additional, Machado-Duque, Manuel Enrique, additional, Gaviria-Mendoza, Andrés, additional, Sánchez-Ramírez, Nicolás, additional, Usma-Valencia, Andrés Felipe, additional, Rodríguez-Martínez, Esteban, additional, Rengifo-Franco, Eliana, additional, Forero-Supelano, Víctor Hugo, additional, Gómez-Ramirez, Diego Mauricio, additional, and Sabogal-Ortiz, Alejandra, additional

Published
2021
Full Text
View/download PDF

34. Detección de errores de medicación mediante un programa de seguimiento y minimización en pacientes ambulatorios de Colombia, 2018-2019

Author

Machado-Duque, Manuel Enrique, primary, Machado-Alba, Jorge Enrique, additional, Gaviria-Mendoza, Andrés, additional, Valladales-Restrepo, Luis Fernando, additional, Parrado-Fajardo, Ilsa Yadira, additional, Ospina-Castellanos, Mauren, additional, Rojas-Chavarro, Luisa Fernanda, additional, and López-Rincón, John Alexander, additional

Published
2021
Full Text
View/download PDF

42. Frecuencia de la potencial interacción entre trimetoprim/sulfametoxazol y espironolactona por riesgo de hyperkalemia en pacientes colombianos

Author

Machado-Alba, Jorge Enrique, Machado-Duque, Manuel Enrique, Gaviria-Mendoza, Andrés, Restrepo-López, Juan Sebastián, and Benítez-Mejía, Juan Felipe

Subjects
espironolactona, spironolactone, geriatrics, hiperpotasemia, farmacoepidemiologia (fuente DeCS), combinación trimetoprim-sulfametoxazol, geriatria, hyperkalemia, trimethoprim-sulfamethoxazole combination, pharmacoepidemiology (DeCS source)
Abstract

Resumen Introducción: se ha descrito el riesgo aumentado de muerte súbita y hospitalización por hyperkalemia en pacientes que consumen medicamentos ahorradores de potasio y trimetoprim, motivo por el cual se buscó determinar la frecuencia de la potencial interacción entre espironolactona y trimetoprim-sulfametoxazol en pacientes mayores de 60 años de Colombia. Métodos: estudio observacional. De una base de datos de 3.6 millones de personas se seleccionaron pacientes mayores de 60 años que recibieron espironolactona de manera ambulatoria por al menos tres meses consecutivos y pacientes con prescripción de trimetoprim-sulfametoxazol entre el 1° de agosto de 2014 y 31 de julio de 2015. Posteriormente se identificaron aquellos con prescripción conjunta durante un mismo mes. Se incluyeron variables sociodemográficas, uso concomitante de inhibidores de sistema renina angiotensina, diuréticos e inotrópicos. Resultados: durante el año de estudio, se encontraron 8941 pacientes mayores de 60 años con prescripción continua de espironolactona, y 8028 pacientes con trimetoprim-sulfametoxazol. Su prescripción conjunta fue detectada en 77 pacientes (0.8% de pacientes con espironolactona), con una incidencia acumulada de 0.86 casos por 100 pacientes-espironolactona/año. La edad promedio de estos pacientes fue 79.1 ± 14 años, 57.1% fueron hombres, y la ciudad con más presentación de casos fue Cali (13% del total). El 68.8% de los casos tuvieron además medicación concomitante con losartan y 62.3% con furosemida. Conclusiones: la interacción entre espironolactona y trimetoprim-sulfametoxazol en una población colombiana, es relativamente poco frecuente; sin embargo, debido a los riesgos a los que se expone el paciente anciano es relevante por sus implicaciones en morbilidad y mortalidad, requiriendo ser conocida y monitoreada por el médico prescriptor. (Acta Med Colomb 2017; 42: 189-192). Abstract Introduction: The increased risk of sudden death and hospitalization due to hyperkalemia in patients consuming potassium-sparing drugs and trimethoprim has been described. Therefore, the frequency of the potential interaction between spironolactone and trimethoprim-sulfamethoxazole in patients older than 60 years of Colombia was sought. Methods: observational study. From a database of 3.6 million people, patients older than 60 years who received spironolactone on an outpatient basis for at least three consecutive months and patients with a prescription for trimethoprim-sulfamethoxazole between 08/01/2014 and 07/31/2015 were selected. Subsequently, those with joint prescription during the same month were identified. Sociodemographic variables, concomitant use of renin angiotensin system inhibitors, diuretics and inotropes were included. Results: During the year of study, 8941 patients older than 60 years with continuous spironolactone prescription, and 8028 patients with trimethoprim-sulfamethoxazole, were found. Its co-prescription was detected in 77 patients (0.8% of patients with spironolactone), with a cumulative incidence of 0.86 cases per 100 patients-spironolactone / year. The mean age of these patients was 79.1 ± 14 years, 57.1% were men, and the city with the most cases was Cali (13% of the total). 68.8% of the cases also had concomitant medication with losartan and 62.3% with furosemide. Conclusions: The interaction between spironolactone and trimethoprim-sulfamethoxazole in a Colombian population is relatively infrequent; however, due to the risks to which the elderly patient is exposed, it is relevant because of its morbidity and mortality implications, requiring to be known and monitored by the prescribing physician. (Acta Med Colomb 2017; 42:189-192).

Published
2017

44. Polypharmacy, An Unfinished Term

Author

Machado-Alba, Jorge Enrique, primary, Ayala-Torres, Juan Daniel, additional, Gaviria-Mendoza, Andrés, additional, Machado-Duque, Manuel Enrique, additional, and Castro-Rodríguez, Alejandro, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results